IPP Bureau
GSK expands RSV vaccine to younger adults in US, targeting high-risk 18–49 age group
By IPP Bureau - March 16, 2026
Previously, Arexvy was authorized for adults 60 and older, and for those 50–59 with heightened risk
Virta Health shows nutrition therapy may extend life in advanced pancreatic cancer
By IPP Bureau - March 16, 2026
The trial enrolled patients with stage IV pancreatic cancer, where median life expectancy is just 6 to 12 months
Aptar Pharma teams up with COVIRIX Medical to explore next-generation antiviral inhaler
By IPP Bureau - March 16, 2026
COVIRIX Medical says its broad-spectrum antiviral portfolio has already shown positive virology results against key pandemic threats
C2N Diagnostics expands Alzheimer’s blood test to South Korea via BeauBrain partnership
By IPP Bureau - March 16, 2026
Under the agreement, healthcare professionals in the country will gain access to C2N’s PrecivityAD2 blood test
First patient dosed in trial of novel drug targeting limb-threatening artery disease
By IPP Bureau - March 16, 2026
The trial will enroll up to 42 patients in Finland across four cohorts
Abbott study shows continuous glucose monitoring outperforms fingersticks in Type 2 diabetes
By IPP Bureau - March 16, 2026
This study demonstrates the power of real-time glucose information for people with Type 2 diabetes treated with basal insulin
Zuellig Pharma expands Cialis footprint across Asia
By IPP Bureau - March 16, 2026
The expanded ownership is expected to improve access to Cialis for millions of men in Asia affected by ED and BPH
QIAGEN bags FDA nod for full GI testing on QIAstat-Dx Rise system
By IPP Bureau - March 16, 2026
The approval means US laboratories can now run both respiratory and gastrointestinal panels on the high-throughput QIAstat-Dx Rise
Finerenone hits major goal in Phase III FIND-CKD trial
By IPP Bureau - March 16, 2026
There are limited treatment options available for patients living with non-diabetic CKD, and the unmet need is high for new treatments to delay kidney disease progression and reduce cardiovascular risk
Cadila Pharmaceuticals marks 75-year journey of global healthcare innovation
By IPP Bureau - March 16, 2026
Cadila Pharmaceuticals’ journey has been marked by several milestones, including the development of indigenous formulations, expansion into global markets, and the creation of robust manufacturing and R&D capabilities
Dr. Jitendra Singh lays Foundation for Rs 600 crore Orchid Bio-Pharma plant in Kathua
By IPP Bureau - March 16, 2026
The facility will manufacture the critical antibiotic intermediate Amino Cephalosporanic Acid (ACA), a key component in the production of cephalosporin antibiotics
Glenmark Pharmaceuticals USA to launch Potassium Phosphates Injection USP in multiple vial sizes
By IPP Bureau - March 16, 2026
The product is bioequivalent and therapeutically equivalent to Fresenius Kabi’s reference drug (NDA 212832)
China’s NMPA approves Zydus-licensed anaemia drug Desidustat
By IPP Bureau - March 15, 2026
Desidustat tablets are a novel oral HIF-PHI approved for treating anaemia in non-dialysis adult CKD patients
